-+ 0.00%
-+ 0.00%
-+ 0.00%

Barclays Maintains Overweight on Iovance Biotherapeutics, Raises Price Target to $18

Benzinga·10/13/2026 16:15:21
Listen to the news
Barclays analyst Etzer Darout maintains Iovance Biotherapeutics (NASDAQ:IOVA) with a Overweight and raises the price target from $15 to $18.